Browse studies

Find your next paid study

816 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

Estimated

~$10 – $8,750

Mersana TherapeuticsNCT05514717

Phase 1

A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intol…

B-cell MalignancyChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+5 more

Estimated

~$10 – $8,750

Carna Biosciences, Inc.NCT05602363

Observational

Esophageal Temperature Dynamics and Injury During Pulmonary Vein Isolation With Temperature Controlled Very-High-Power Short-Duration Lesions Using the Novel Q-DOT Micro Ablation Catheter

This study will assess how two different ablation strategies, using two different ablation catheters during catheter ablation for paroxysmal atrial fibrillatio…

Atrial Fibrillation Paroxysmal

Estimated

~$10 – $6,250

Cedars-Sinai Medical CenterNCT06392932

Phase 1

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and effica…

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more

Estimated

~$10 – $8,750

Tanabe Pharma America, Inc.

Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphoc…

Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)

Estimated

~$10 – $750

H. Lee Moffitt Cancer Center and Research InstituteNCT07030400

Phase 1

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial

Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperati…

Lung CancerNon Small Cell Lung CancerLung Cancer Recurrent

Estimated

~$10 – $6,250

Rutgers, The State University of New JerseyNCT06979661

Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pr…

Cancer of Head and NeckLung Cancer, Nonsmall CellSmall-cell Lung Cancer+8 more

Estimated

~$10 – $1,050

Cofactor Genomics, Inc.NCT04510129

Phase 1

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and to…

Non-Small Cell Lung CancerColorectal CancerBreast Cancer+3 more

Estimated

~$10 – $8,750

Fate TherapeuticsNCT07216105

Phase 1

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an e…

Breast NeoplasmsCarcinoma, Non-Small-Cell LungSolid Carcinoma

Estimated

~$10 – $8,750

Xadcera Biopharmaceutical (Suzhou) Co., Ltd.NCT06475937

Observational

Efficacy of the Artificial Intelligence HeartBot II in Increasing Awareness and Knowledge of Heart Attack in Women: Study Protocol for a Randomized Controlled Trial With a Waitlist Control

The goal of this clinical trial is to find out whether an app-based program called HeartBot II, which uses an artificial intelligence (AI) chatbot, can help im…

Participants Must be Women Aged 25 Years or OlderParticipants Should Have no Self-reported History of Heart Disease or StrokeParticipants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease+4 more

Estimated

~$10 – $5,625

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despit…

Non-small Cell Lung CancerEsophageal CancerGastric Cancer+3 more

Estimated

~$10 – $750

University of Missouri-ColumbiaNCT02838836

Phase 2

A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)

This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progr…

Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

BioNTech SENCT06841055